Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionNbc Securities, Inc.
Latest Disclosed Ownership247 shares
Latest Disclosed Value $ 110,295
Nbc Securities, Inc. reports 0.41% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 14, 2026 - Nbc Securities, Inc. filed a 13F-HR form disclosing ownership of 247 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $110,295 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 246 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 0.41% during the quarter. The current value of the position is $110,367 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-14 2026-03-31 13F VERTEX PHARMACEUTICALS COMMON STK 92532F100 247 1 0.41 110 -0.90 0.0083
2026-01-29 2025-12-31 13F VERTEXPHARMACEUTICALSINC COMMONSTK 92532F100 246 58 30.85 112 52.05 0.0084
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COMMON STK 92532F100 188 -172 -47.78 74 0.0057
2025-07-08 2025-06-30 13F VERTEX PHARMACEUTICALS COMMON STK 92532F100 360 15 4.35 0 0.0131
2025-04-09 2025-03-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 345 345 0 0.0142
2025-01-22 2024-12-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 0 -160 -100.00 0 0.0000
2024-10-15 2024-09-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 160 41 34.45 0 0.0062
2024-07-10 2024-06-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 119 0 0.00 0 0.0050
2024-04-05 2024-03-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 119 19 19.00 0 0.0046
2024-02-07 2023-12-31 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 100 1 1.01 0 0.0040
2023-11-03 2023-09-30 13F VERTEX PHARMACEUTICALS IN Stock 92532F100 99 99 0 0.0037
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.